A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects with Relapsed and Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051230108

Enrollment

Registered

2023-10-04

Start date

2023-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and refractory multiple myeloma

Interventions

CC-93269

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -History of multiple myeloma with relapsed and refractory disease -Eastern Cooperative Oncology Group Performance Status of 0 or 1 -Must have measurable disease as determined by the central laboratory

Exclusion criteria

Exclusion criteria: -Symptomatic central nervous system involvement of multiple myeloma -Prior autologous stem cell transplant <= 3 months prior -Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning <= 12 months prior -History of concurrent second cancers requiring active, ongoing systemic treatment

Design outcomes

Primary

Measure	Time frame
To determine the safety and tolerability of CC-93269, in subjects with relapsed and refractory MM.	—

Secondary

Measure	Time frame
To evaluate the preliminary efficacy of CC-93269 in relapsed and refractory MM, etc.	—

Countries

Germany, Italy, Japan, Spain, Sweden, United States

Contacts

Public ContactJin Hayakawa

Bristol-Myers Squibb

MG-JP-RCO-JRCT@bms.com+81-120-093-507

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026